Back to Sites University of Florida Jacksonville Site Number 5051 Address University of Florida Jacksonville 653-1 West 8th Street LRC 3rd Floor Jacksonville, FL 32209 United States of America IMPAACT Members at this Site Joseph Mims CAB Member Ana Alvarez Co-Investigator Bernadette Belgado Co-Investigator Feroz Bhinde Co-Investigator Peggy Borum Co-Investigator Denise Darracott Co-Investigator Carol Fulton Co-Investigator Nizar Maraqa Co-Investigator Ayesha Mirza Co-Investigator Elaine Poon Co-Investigator Saniyyah Mahmoudi CRS Coordinator Mobeen Rathore CRS Leader Michele Burke CRS Staff Angela Monroe CRS Staff Laura Armas-Kolostroubis Investigator Renette Dasher Investigator Isaac Delke Investigator Michael Miller Investigator Kristi Stowers Investigator Elizabeth Martino Laboratory Technician/Technologist Diane Swindell Research Assistant Geraldine (Geri) Thomas Research Nurse Mobeen Rathore Site Leader Margot Althuis-Brown Study Coordinator Indira Becerrit Study Coordinator Doriana Boro Study Coordinator Barbara Millwood Study Coordinator Studies at this Site IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Therapeutics Study Status Enrolling IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV DAIDS Number 38693 Research Area Cure and Immunotherapy Study Status Enrolling IMPAACT 2017: MOCHA DAIDS Number 30070 Research Area Therapeutics Study Status Closed to Accrual IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 DAIDS Number 38962 Research Area Therapeutics Study Status Pending IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in People with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status In Development Pagination Previous page Prev Page 1 Current page 2
IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Therapeutics Study Status Enrolling
IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV DAIDS Number 38693 Research Area Cure and Immunotherapy Study Status Enrolling
IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 DAIDS Number 38962 Research Area Therapeutics Study Status Pending
IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in People with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status In Development